Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The treatment is safe and shows promise for metastatic breast cancer.

Brepocitinib reduces interferon signaling in hidradenitis suppurativa patients.

Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.

Combining topical delgocitinib with a 308-nm excimer laser can effectively treat severe alopecia areata and vitiligo.

Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.

Cancer treatments often cause skin, nail, and hair problems.

Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.

Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.

PLD is an effective and safer alternative for treating breast cancer.

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

High-dose methotrexate can cause severe skin and nail issues.

The rash resolved after stopping ponatinib.

The combination of encorafenib and binimetinib caused few skin issues.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

The combination therapy is effective and well-tolerated for treating esophageal cancer.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

CVP therapy showed moderate success in treating advanced non-Hodgkin's lymphoma, but more intensive treatment is needed for better outcomes.